Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
- First oral short-course treatment for relapsing
<p>- remitting multiple sclerosis (RRMS) now approved in Canada, which has one of the highest rates of MS in the world (1);
<p>- Mavencladhas shown sustained clinical efficacy with a duration of oral treatment of 20 days over 2 years;
<p>- The approval of Mavenclad by Health Canada follows the recent approval of Mavenclad across Europe by the European Commission.
<p>- remitting multiple sclerosis (RRMS) now approved in Canada, which has one of the highest rates of MS in the world (1);
<p>- Mavencladhas shown sustained clinical efficacy with a duration of oral treatment of 20 days over 2 years;
<p>- The approval of Mavenclad by Health Canada follows the recent approval of Mavenclad across Europe by the European Commission.
- 04.12.2017, 10:39
- Kategoria: Zdrowie i styl życia
- Źródło: PR Newswire
